| Name | Title | Contact Details |
|---|
In January 2014, Jordan Hospital joined the Beth Israel Deaconess Medical Center family of hospitals and become Beth Israel Deaconess Hospital-Plymouth. In 1899, a group of leading citizens from Plymouth saw a need to build a hospital to serve residents and pursued the idea of "a hospital on the hill". They approached retail tycon, philanthropist, and summer resident Eben Jordan, of the Jordan Marsh Company, and he donated $20,000 to build was was to become Jordan Hospital. In December 1903, Jordan Hospital opened its doors to the first patients and has remained a community hospital ever since. In 2014, Jordan Hospital become Beth Israel Deaconess Hospital-Plymouth and remains a private, not-for-profit hospital. We treat all patients, regardless of ability to pay. We proudly serve the communities of Bourne, Carver, Duxbury, Halifax, Kingston, Lakeville, Pembroke, Plympton, Plymouth, Marshfield, Middleboro, Sandwich and Wareham, as well as numerous visitors to our historic area. Beth Israel Deaconess-Plymouth is an affiliate of Beth Israel Deaconess Medical Center in Boston.
Founded in 1975, CHS is the industry's trusted provider of onsite health centers and national examination programs.
Prototypes Warn is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highlights Healthcare is a company that provides diagnosis, early intervention, and ABA therapy services to bring meaningful and positive change to learners with Autism Spectrum Disorder.
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.